CRH plc has rebounded about 9% in five days after a third-quarter report that cut full-year net income guidance but came with a $6 billion buyback. The balance of evidence still leans negative for the next two to six weeks. At $93.84 the stock is overbought, with a 14-day RSI of 80, inside a weekly downtrend. Conviction is low, 1 of 4, because CRH has outpaced the S&P 500 over 50 days, which cuts against that reading.
Why it matters
The October 29, 2026 results were mixed. Revenue was $11.4 billion, up 3% but short of the $11.56 billion estimate, and adjusted EPS of $2.09 beat the $2.03 consensus. Net income fell 22% to $1.2 billion on $178 million of impairment losses, and full-year net income guidance was cut to $3.1–$3.3 billion from $3.9–$4.1 billion. CRH also closed its roughly $8.5 billion Arcosa acquisition and announced the buyback, per the company's results release.
The reaction showed how much bad news was already in the price. Shares rallied 4.1% to $90.10 after a sharp intraday reversal, despite the guidance cut. A stock that rises on a cut had largely discounted it: CRH was still down about 25% for the year and 28.6% below its 52-week high of $131.38. The advance then carried to a $96.59 close on November 2. Today shares are down 2.85% on volume 57.6% below the 20-day average, while SPY is up 0.23%. No news explains today's drop, and on volume that thin it says little.
The five-day move was the stock's own. CRH gained 9.3% while SPY fell 2.1%, so the market was a headwind, not the source. No sector comparison is available in the data, so the move cannot be split further. What the news does account for is the earnings reaction, the buyback, and a price-target increase on November 2.
The debate comes down to pricing against costs. The bullish side is Truist, which lifted its price target to $120 from $105 and kept a Buy rating, expecting substantial price increases in early 2027 to offset inflating costs. The cautious side comes from the quarter itself. Adjusted EBITDA was flat at $2.7 billion, with pricing and acquisitions only offsetting cost inflation, and the guidance cut shows earnings power is falling short. The Arcosa deal was financed with term loans, bridge facilities and cash.
On valuation, 24 analysts rate the stock a strong buy with a mean target of $120.59, which puts the price 22.2% below it. The spread is wide, from $95 to $160, and even the lowest target sits barely above today's price. The consensus is betting on 2027 pricing, which this quarter has not yet confirmed.
What the evidence says
The long-term thesis is weakened, not broken. The price is below its 40-week average and below the 200-day average of $103.82, and it is down 18.8% over six months and 24.9% this year. The stock is in a downtrend that has been interrupted by a sharp counter-trend recovery of 18.5% off the $79.20 low. It is back above the 10-week average, but that is a bounce within a decline, not a new uptrend.
For the next two to six weeks the balance of evidence leans negative, with low conviction at 1 of 4. The case rests on a rally inside the weekly downtrend that has reached overbought, with the RSI at 80.35. The price sits just under $98.34, where sellers have appeared on earlier rallies. Only one of four conviction points supports the call, so it is a modest lean, not a strong signal.
The strongest case against it is relative strength. CRH leads the S&P 500 by 9.5% over 50 days, it is above its 10-week average, a $6 billion buyback supports the shares, and Truist's 2027 pricing argument gives buyers a story. That relative strength is why conviction is not higher. It does not tip the balance, because it starts from a low base: over 200 days the stock still trails the index by 13.2%, and it remains well below its 200-day average.
Levels that matter
The structure holds below $98.34, the swing zone where sellers have shown up on rallies. Above it sit the round $100.00 and a second swing zone at $100.42. A weekly close above $100.42 would end the downtrend structure. Further resistance lies at $102.14 and the 200-day average at $103.82.
The downside breakout level is a daily close below $90.00. From there the first target is the 50-day average at $87.17, a reward-to-risk of only 0.3 to 1. The second is the 52-week low at $79.20, at 1.2 to 1. The stop is $99.08, which is the $98.34 swing zone plus a quarter of the 2.94 daily range (ATR). The math does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target below the 52-week low, or a stop far closer to $90.
What would change the picture
A weekly close above $100.42 would change the picture, as it would clear the swing zone that caps the rally. The non-price fact that would most likely do it is evidence that the early-2027 price increases are being accepted by customers. That would support Truist's argument and show that pricing can outrun cost inflation.
What to watch
- Next earnings: the date is not yet in the data. The last report was October 29, 2026. The number that matters is whether adjusted EBITDA moves above the flat $2.7 billion, and whether net income stays within the cut $3.1–$3.3 billion guidance.
- Sector events: no sector benchmark is available, so peer pricing announcements in building materials, and any news on Arcosa integration or its debt financing, are the items that could move the stock before its own news.
- Valuation: at $93.84 the stock trades 22.2% below the $120.59 mean target, with targets from $95 to $160. The gap closes only if 2027 pricing arrives.